Travere reports 5-year DUPLEX extension data showing sustained proteinuria reduction with FILSPARI in FSGS

Travere Therapeutics, Inc.

Travere Therapeutics, Inc.

TVTX

0.00
  • Travere Therapeutics released long-term open-label extension results from the Phase 3 DUPLEX study of FILSPARI in FSGS; data were presented at ERA 2026 on June 3-6.
  • Patients who stayed on FILSPARI showed sustained reductions in protein leakage in urine, supporting a durable treatment effect over years.
  • Participants who switched from irbesartan to FILSPARI in the extension saw a rapid drop in protein leakage that held up over time.
  • The update strengthens FILSPARI’s positioning in FSGS care, with tolerability broadly consistent with prior findings during extended follow-up.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Travere Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260604838591) on June 04, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.